Interplay between estrogen receptor and AKT in Estradiol-induced alternative splicing

BMC Medical Genomics

Volumn 6, Issue 1, 2013, Pages

  Bhat Nakshatri, Poornima ^a   Song, Eun Kyung ^a   Collins, Nikail R ^a   Uversky, Vladimir N ^a,e   Dunker, A Keith ^a,b   O'Malley, Bert W ^c   Geistlinger, Tim R ^d,f   Carroll, Jason S ^d,g   Brown, Myles ^d   Nakshatri, Harikrishna ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f Amyris   (United States)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FAS ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; KERATINOCYTE GROWTH FACTOR; MESSENGER RNA; PROTEIN KINASE B;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; AXIN 1 GENE; BINDING AFFINITY; BINDING SITE; CD44 ANTIGEN GENE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAS GENE; FGFR2 GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SEQUENCE ANALYSIS; TRANSCRIPTION REGULATION;

ALTERNATIVE SPLICING; ANTIGENS, CD44; ANTIGENS, CD95; BINDING SITES; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HUMANS; MCF-7 CELLS; MUTATION; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84878677222     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-6-21     Document Type: Article

References (61)

1. Endocrine-responsive breast cancer and strategies for combating resistance. Ali S, Coombes RC, Nat Rev Cancer 2002 2 101 112 10.1038/nrc721 12635173
2. Biological determinants of endocrine resistance in breast cancer. Musgrove EA, Sutherland RL, Nat Rev Cancer 2009 9 631 643 10.1038/nrc2713 19701242
3. P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Rayala SK, Talukder AH, Balasenthil S, Tharakan R, Barnes CJ, Wang RA, Aldaz M, Khan S, Kumar R, Cancer Res 2006 66 1694 1701 10.1158/0008-5472.CAN-05-2922 16452229
4. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Lee H, Bai W, Mol Cell Biol 2002 22 5835 5845 10.1128/MCB.22.16.5835-5845.2002 12138194
5. Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Park KJ, Krishnan V, O'Malley BW, Yamamoto Y, Gaynor RB, Mol Cell 2005 18 71 82 10.1016/j.molcel.2005.03.006 15808510
6. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H, J Biol Chem 2001 276 9817 9824 10.1074/jbc.M010840200 11139588
7. Activation of the estrogen receptor through phosphorylation by mitogen- activated protein kinase. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, et al. Science 1995 270 1491 1494 10.1126/science.270.5241.1491 7491495
8. Alternative isoform regulation in human tissue transcriptomes. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB, Nature 2008 456 470 476 10.1038/nature07509 18978772
9. Cell signalling and the control of pre-mRNA splicing. Shin C, Manley JL, Nat Rev Mol Cell Biol 2004 5 727 738 10.1038/nrm1467 15340380
10. Understanding alternative splicing: towards a cellular code. Matlin AJ, Clark F, Smith CW, Nat Rev Mol Cell Biol 2005 6 386 398 10.1038/nrm1645 15956978
11. Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Blaustein M, Pelisch F, Tanos T, Munoz MJ, Wengier D, Quadrana L, Sanford JR, Muschietti JP, Kornblihtt AR, Caceres JF, et al. Nat Struct Mol Biol 2005 12 1037 1044 10.1038/nsmb1020 16299516
12. Alternative splicing: multiple control mechanisms and involvement in human disease. Caceres JF, Kornblihtt AR, Trends Genet 2002 18 186 193 10.1016/S0168-9525(01)02626-9 11932019
13. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. David CJ, Manley JL, Genes Dev 2010 24 2343 2364 10.1101/gad.1973010 21041405
14. Alternatively spliced products CC3 and TC3 have opposing effects on apoptosis. Whitman S, Wang X, Shalaby R, Shtivelman E, Mol Cell Biol 2000 20 583 593 10.1128/MCB.20.2.583-593.2000 10611237
15. An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Gabut M, Samavarchi-Tehrani P, Wang X, Slobodeniuc V, O'Hanlon D, Sung HK, Alvarez M, Talukder S, Pan Q, Mazzoni EO, et al. Cell 2011 147 132 146 10.1016/j.cell.2011.08.023 21924763
16. Cancer-associated regulation of alternative splicing. Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L, Durand M, Couture S, Froehlich U, Lapointe E, et al. Nat Struct Mol Biol 2009 16 670 676 10.1038/nsmb.1608 19448617
17. Identification of alternative splicing markers for breast cancer. Venables JP, Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Koh C, Gervais-Bird J, Lapointe E, Froehlich U, Durand M, et al. Cancer Res 2008 68 9525 9531 10.1158/0008-5472.CAN-08-1769 19010929
18. Exon-level microarray analyses identify alternative splicing programs in breast cancer. Lapuk A, Marr H, Jakkula L, Pedro H, Bhattacharya S, Purdom E, Hu Z, Simpson K, Pachter L, Durinck S, et al. Mol Cancer Res 2010 8 961 974 10.1158/1541-7786.MCR-09-0528 20605923
19. Frequent pathway mutations of splicing machinery in myelodysplasia. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, et al. Nature 2011 478 64 69 10.1038/nature10496 21909114
20. Alternative splicing in concert with protein intrinsic disorder enables increased functional diversity in multicellular organisms. Romero PR, Zaidi S, Fang YY, Uversky VN, Radivojac P, Oldfield CJ, Cortese MS, Sickmeier M, LeGall T, Obradovic Z, Dunker AK, Proc Natl Acad Sci USA 2006 103 8390 8395 10.1073/pnas.0507916103 16717195
21. Coordinate regulation of transcription and splicing by steroid receptor coregulators. Auboeuf D, Honig A, Berget SM, O'Malley BW, Science 2002 298 416 419 10.1126/science.1073734 12376702
22. A subset of nuclear receptor coregulators Act as coupling proteins during synthesis and maturation of RNA transcripts. Auboeuf D, Dowhan DH, Dutertre M, Martin N, Berget SM, O'Malley BW, Mol Cell Biol 2005 25 5307 5316 10.1128/MCB.25.13.5307-5316.2005 15964789
23. Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related proteins CAPERalpha and CAPERbeta. Dowhan DH, Hong EP, Auboeuf D, Dennis AP, Wilson MM, Berget SM, O'Malley BW, Mol Cell 2005 17 429 439 10.1016/j.molcel.2004.12.025 15694343
24. Cotranscriptional splicing potentiates the mRNA production from a subset of estradiol-stimulated genes. Bittencourt D, Dutertre M, Sanchez G, Barbier J, Gratadou L, Auboeuf D, Mol Cell Biol 2008 28 5811 5824 10.1128/MCB.02231-07 18644870
25. Splicing potentiation by growth factor signals via estrogen receptor phosphorylation. Masuhiro Y, Mezaki Y, Sakari M, Takeyama K, Yoshida T, Inoue K, Yanagisawa J, Hanazawa S, O'Malley BW, Kato S, Proc Natl Acad Sci USA 2005 102 8126 8131 10.1073/pnas.0503197102 15919818
26. Comprehesive molecular portraits of humna breast cancers. Koboldt DC, Nature 2012 490 61 70 10.1038/nature11412 23000897
27. Whole-genome analysis informs breast cancer response to aromatase inhibition. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, et al. Nature 2012 486 353 360 22722193
28. AKT Alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer. Bhat-Nakshatri P, Wang G, Appaiah H, Luktuke N, Carroll JS, Geistlinger TR, Brown M, Badve S, Liu Y, Nakshatri H, Mol Cell Biol 2008 28 7487 7503 10.1128/MCB.00799-08 18838536
29. ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. Welboren WJ, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, Span PN, Stunnenberg HG, EMBO J 2009 28 1418 1428 10.1038/emboj.2009.88 19339991
30. GEMS (Gene Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17beta-estradiol in MCF-7 cells. Ochsner SA, Steffen DL, Hilsenbeck SG, Chen ES, Watkins C, McKenna NJ, Cancer Res 2009 69 23 26 19117983
31. An oestrogen-receptor-alpha-bound human chromatin interactome. Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, Orlov YL, Velkov S, Ho A, Mei PH, et al. Nature 2009 462 58 64 10.1038/nature08497 19890323
32. Roles of fibroblast growth factor receptors in carcinogenesis. Haugsten EM, Wiedlocha A, Olsnes S, Wesche J, Mol Cancer Res 2010 8 1439 1452 10.1158/1541-7786.MCR-10-0168 21047773
33. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, et al. Nat Genet 2007 39 870 874 10.1038/ng2075 17529973
34. Genome-wide association study identifies novel breast cancer susceptibility loci. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, et al. Nature 2007 447 1087 1093 10.1038/nature05887 17529967
35. An alternative splicing network links cell-cycle control to apoptosis. Moore MJ, Wang Q, Kennedy CJ, Silver PA, Cell 2010 142 625 636 10.1016/j.cell.2010.07.019 20705336
36. Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. He X, Ee PL, Coon JS, Beck WT, Clin Cancer Res 2004 10 4652 4660 10.1158/1078-0432.CCR-03-0439 15269137
37. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Chen M, Manley JL, Nat Rev Mol Cell Biol 2009 10 741 754 19773805
38. Evolution of SR protein and hnRNP splicing regulatory factors. Busch A, Hertel KJ, Wiley Interdiscip Rev RNA 2012 3 1 12 21898828
39. The links between axin and carcinogenesis. Salahshor S, Woodgett JR, J Clin Pathol 2005 58 225 236 10.1136/jcp.2003.009506 15735151
40. Aberrant processing of Fas transcripts in adult T-cell leukemia: a possible role in tumor cell survival. Tawara M, Maeda T, Yamada Y, Harasawa H, Tsuruda K, Sugahara K, Moriuchi R, Tomonaga M, Kamihira S, Cancer Lett 2003 193 235 242 10.1016/S0304-3835(03)00006-5 12706882
41. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Cha JY, Lambert QT, Reuther GW, Der CJ, Mol Cancer Res 2008 6 435 445 10.1158/1541-7786.MCR-07-0187 18337450
42. Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. Moffa AB, Ethier SP, J Cell Physiol 2007 210 720 731 10.1002/jcp.20880 17133345
43. Preferential alternative splicing in cancer generates a K-sam messenger RNA with higher transforming activity. Itoh H, Hattori Y, Sakamoto H, Ishii H, Kishi T, Sasaki H, Yoshida T, Koono M, Sugimura T, Terada M, Cancer Res 1994 54 3237 3241 8205545
44. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, et al. Cancer Res 2006 66 11954 11966 10.1158/0008-5472.CAN-06-1666 17178894
45. Cellular survival: a play in three Akts. Datta SR, Brunet A, Greenberg ME, Genes Dev 1999 13 2905 2927 10.1101/gad.13.22.2905 10579998
46. Regulation of apoptosis by alternative pre-mRNA splicing. Schwerk C, Schulze-Osthoff K, Mol Cell 2005 19 1 13 10.1016/j.molcel.2005.05.026 15989960
47. Diversification of stem cell molecular repertoire by alternative splicing. Pritsker M, Doniger TT, Kramer LC, Westcot SE, Lemischka IR, Proc Natl Acad Sci USA 2005 102 14290 14295 10.1073/pnas.0502132102 16183747
48. Genome-wide analysis of estrogen receptor binding sites. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, et al. Nat Genet 2006 38 1289 1297 10.1038/ng1901 17013392
49. Whole-genome cartography of estrogen receptor alpha binding sites. Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, Chiu KP, Lipovich L, Barnett DH, Stossi F, et al. PLoS Genet 2007 3 87 10.1371/journal.pgen.0030087 17542648
50. Growth factor stimulation induces a distinct ERalpha cistrome underlying breast cancer endocrine resistance. Lupien MMC, Bailey ST, Eeckhoute J, Cook J, Westerling T, Zhang X, Carroll JS, Rhodes DR, Liu XS, Brown M, Genes Dev 2010 24 in press
51. Epigenetics in alternative pre-mRNA splicing. Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T, Cell 2011 144 16 26 10.1016/j.cell.2010.11.056 21215366
52. Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6. Raponi M, Kralovicova J, Copson E, Divina P, Eccles D, Johnson P, Baralle D, Vorechovsky I, Hum Mutat 2011 32 436 444 10.1002/humu.21458 21309043
53. Differential recruitment of nuclear receptor coactivators may determine alternative RNA splice site choice in target genes. Auboeuf D, Dowhan DH, Kang YK, Larkin K, Lee JW, Berget SM, O'Malley BW, Proc Natl Acad Sci USA 2004 101 2270 2274 10.1073/pnas.0308133100 14982999
54. Molecular cloning and characterization of CAPER, a novel coactivator of activating protein-1 and estrogen receptors. Jung DJ, Na SY, Na DS, Lee JW, J Biol Chem 2002 277 1229 1234 10.1074/jbc.M110417200 11704680
55. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Moffa AB, Tannheimer SL, Ethier SP, Mol Cancer Res 2004 2 643 652 15561780
56. Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Pond AC, Herschkowitz JI, Schwertfeger KL, Welm B, Zhang Y, York B, Cardiff RD, Hilsenbeck S, Perou CM, Creighton CJ, et al. Cancer Res 2010 70 4868 4879 10.1158/0008-5472.CAN-09-4404 20501844
57. FAS activation induces dephosphorylation of SR proteins; dependence on the de novo generation of ceramide and activation of protein phosphatase 1. Chalfant CE, Ogretmen B, Galadari S, Kroesen BJ, Pettus BJ, Hannun YA, J Biol Chem 2001 276 44848 44855 10.1074/jbc.M106291200 11502750
58. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, et al. Cell 2007 130 811 823 10.1016/j.cell.2007.07.025 17803905
59. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M, EMBO J 2008 27 535 545 10.1038/sj.emboj.7601984 18219273
60. CD95 promotes tumour growth. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, Peter ME, Nature 2010 465 492 49 10.1038/nature09075 20505730
61. Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function. Bhat-Nakshatri P, Campbell RA, Patel NM, Newton TR, King AJ, Marshall MS, Ali S, Nakshatri H, Br J Cancer 2004 90 853 859 10.1038/sj.bjc.6601541 14970864